Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 10, 2011

View Archived Issues

TSRL discloses preclinical data on neuraminidase inhibitor prodrugs

GSK FLAP inhibitor attenuates allergen-induced asthma responses in phase II trials

MRI technique may aid in differentiating Gulf War illness variants

Study identifies SNPs associated with severity of A/H1N1/2009 influenza in children

Protalix Biotherapeutics patents novel cross-linked multimeric proteins for Gaucher's disease

Promising phase III data disclosed on VX-770 in CF

AXL-1717 benefits patients with advanced-stage NSCLC in phase I trial

Scientists in Taiwan identify miRNA signature associated with incidence of oral cancer

Amgen discloses novel series of beta-secretase 1 inhibitors

Novel prostanoid DP1 receptor antagonists synthesized by Sanofi

New TRPA1 channel antagonists presented by Glenmark Pharmaceuticals

Novel agents for bacterial infections claimed

New SSAO inhibitors described by Proximagen

FDA approves Merck & Co.'s Juvisync

Epix Pharmaceuticals and Amgen S1P1 program assets to be offered for sale

BAY-1017858 shows promise in vitro and in vivo

Abbott enrolls first patients in EXCEL trial evaluating Xience everolimus-eluting stents

FDA and Starpharma agree on phase III program for VivaGel

Victoza launched in China

Trimel Pharmaceuticals provides update on phase II Vibro-Tactile Stimulation trial

Hybrigenics and Servier sign license and collaboration agreement covering multiple fields

Adherex to discuss development of sodium thiosulfate with FDA advisory committee

Biotron provides results from preliminary analysis of BIT-225 study

Paladin Labs completes Labopharm acquisition

Combivent Respimat approved in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM
BioWorld
Cytokinetics Inc. scored U.S. FDA marketing clearance Dec. 19 for Myqorzo (aficamten) 5-mg, 10-mg, 15-mg, and 20-mg tablets to improve functional capacity and...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....